Annual report pursuant to Section 13 and 15(d)

Note B - Going Concern and Liquidity

v3.19.1
Note B - Going Concern and Liquidity
12 Months Ended
Dec. 31, 2018
Notes to Financial Statements  
Substantial Doubt about Going Concern [Text Block]
NOTE B- GOING CONCERN AND LIQUIDITY
    
In accordance with Accounting Standard Codification (“ASC”)
205
-
40,
“Presentation of Financial Statements – Going Concern”, the Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within
one
year after the date that the consolidated financial statements are issued. Milestone Scientific has incurred operating losses and negative cash flows from operating activities in virtually each year since its inception. At
December 31, 2018,
the Company’s cash on hand and net current assets decreased to
$.7
million  and
$1.0
million from
$2.6
million and
$5.3
million in
2017,
respectively. Based on the expected cash needed for operating activities, the Company’s current cash and liquidity including the
February 2019
financing is
not
sufficient to finance the  operating requirements for at least the next
12
months from the  filing date.  These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.   
   
Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, and a reduction in operating expenses. However, the Company’s continued operations will depend on its ability to raise additional capital through various potential sources until it achieves profitability, if ever. Management is actively pursuing financing or other strategic plans but can provide
no
assurances that such financing or other strategic plans will be available on acceptable terms, or at all.
 
In
February 2019,
Milestone Scientific consummated a public and private offering of Common Stock. The public offering generated gross proceeds of approximately
$2.0
million through the issuance of
5,715,000
shares of common stock and warrants of
1,428,000
to purchase common shares. Subsequent to the public offering, the underwriter exercised its overallotment option and paid approximately
$198,000
for 
567,400
additional shares. See Note T.
 
Also, in
February 2019,
the Company generated gross proceeds from a private offering of approximately
$250,000
through the issuance of
714,286
shares of common stock and warrants of
178,594
to purchase common shares  to
Bp4
S.p.A., a principal stockholder of Milestone Scientific, that exercised its right to participate on a prorated basis in  the recent public offering.
Bp4’s
CEO is a director of Milestone Scientific and also Chief Executive Officer and Director of Wand Dental, a wholly owned subsidiary of Milestone Scientific. See Note T. 
 
These consolidated financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do
not
include any adjustments to reflect the possible future effects on the recover ability and classification of assets or the amounts and classification of liabilities that
may
result from the inability of the Company to continue as a going concern.